AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29241105 — intervention group
Group type: COMPARATOR
Intervention: Computer-generated individualized feedback letters
Number of subjects: 961
Study 29241105 — intervention group
Group type: COMPARATOR
Intervention: In-person counseling
Number of subjects: 961
Study 28760121 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TA) 10 mg/kg 20 minutes preoperatively and 3 hours after first dose
Number of subjects: 90
Study 28760121 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular tranexamic acid (TA) 3 g locally into surgical site
Number of subjects: 90
Study 28760121 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TA)
Number of subjects: 90
Study 25917434 — intervention group
Group type: EXPERIMENTAL
Intervention: air-Q
Number of subjects: 64
Study 25917434 — intervention group
Group type: COMPARATOR
Intervention: Ambu Aura-i
Number of subjects: 64
Study 23442351 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolongation of life (POL) format for risk communication
Number of subjects: 328
Study 23442351 — intervention group
Group type: COMPARATOR
Intervention: Absolute risk reduction (ARR) format for risk communication
Number of subjects: 328
Study 21620926 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD restored with resin composite
Number of subjects: 80
Study 21620926 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD plus extensive endodontic access, GIC core and resin composite
Number of subjects: 80
Study 21620926 — intervention group
Group type: COMPARATOR
Intervention: Unrestored MOD cavity
Number of subjects: 80
Study 21620926 — intervention group
Group type: COMPARATOR
Intervention: Unrestored MOD cavity plus endodontic access through the occlusal floor
Number of subjects: 80
Study 21620926 — intervention group
Group type: COMPARATOR
Intervention: Unrestored MOD plus endodontic access with axial walls removed
Number of subjects: 80
Study 18363581 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (150 mg, 3 times daily for 1 week after each blood donation)
Number of subjects: 412
Study 18363581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 412
Study 16492219 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (5.25 mg)
Number of subjects: 12
Study 16492219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 12671696 — intervention group
Group type: EXPERIMENTAL
Intervention: Active lozenges (PTA) containing polymyxin E 2 mg, tobramycin 1.8 mg and amphotericin B 10 mg, four times daily during radiotherapy
Number of subjects: 65
Study 12671696 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenges, four times daily during radiotherapy
Number of subjects: 65
Study 12671696 — intervention group
Group type: EXPERIMENTAL
Intervention: Active lozenges (PTA)
Number of subjects: 65
Study 12671696 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenges
Number of subjects: 65
Study 10880416 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 66
Study 10880416 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CPAP)
Number of subjects: 66
Study 8938220 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with cyclophosphamide and methotrexate followed by concomitant 5-fluorouracil and irradiation
Number of subjects: 38
Study 8938220 — intervention group
Group type: COMPARATOR
Intervention: Irradiation alone
Number of subjects: 38
Study 1534876 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil N2O/O2 with 0.25% isoflurane
Number of subjects: 0
Study 1534876 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil N2O/O2 with 0.25% isoflurane
Number of subjects: 0
Study 3694302 — intervention group
Group type: EXPERIMENTAL
Intervention: Gauze dressing
Number of subjects: 301
Study 3694302 — intervention group
Group type: COMPARATOR
Intervention: Uniflex transparent plastic dressing
Number of subjects: 301
Study 3694302 — intervention group
Group type: COMPARATOR
Intervention: Tegaderm transparent plastic dressing
Number of subjects: 301
Study 30574609 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive oral care programme (IOCP)
Number of subjects: 48
Study 30574609 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 48
Study 30574609 — intervention group
Group type: COMPARATOR
Intervention: 0.12% chlorhexidine mouthrinse
Number of subjects: 48
Study 30574609 — intervention group
Group type: COMPARATOR
Intervention: 0.03% triclosan mouthrinse
Number of subjects: 48
Study 26000622 — intervention group
Group type: EXPERIMENTAL
Intervention: Active music therapy (MT) in addition to speech language therapy (SLT)
Number of subjects: 20
Study 26000622 — intervention group
Group type: COMPARATOR
Intervention: Speech language therapy (SLT) alone
Number of subjects: 20
Study 25151488 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg daily during radiation therapy
Number of subjects: 40
Study 25151488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23870627 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 274
Study 23870627 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 274
Study 21389934 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (keppra) as first monotherapy
Number of subjects: 143
Study 21389934 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (keppra) as second or third monotherapy
Number of subjects: 143
Study 17803835 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief eclectic psychotherapy (BEP) in 16 weekly individual sessions
Number of subjects: 20
Study 17803835 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 20
Study 17803835 — intervention group
Group type: EXPERIMENTAL
Intervention: BEP
Number of subjects: 20
Study 19652253 — intervention group
Group type: EXPERIMENTAL
Intervention: Glidewire
Number of subjects: 100
Study 19652253 — intervention group
Group type: EXPERIMENTAL
Intervention: ZipWire
Number of subjects: 100
Study 19652253 — intervention group
Group type: COMPARATOR
Intervention: HiWire
Number of subjects: 100
Study 19652253 — intervention group
Group type: EXPERIMENTAL
Intervention: All guidewires
Number of subjects: 100
Study 15151349 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention groups
Number of subjects: 12
Study 15151349 — intervention group
Group type: COMPARATOR
Intervention: Comparison groups
Number of subjects: 12
Study 15151349 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-specific programs
Number of subjects: 12
Study 15151349 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent programs
Number of subjects: 12
Study 15151349 — intervention group
Group type: COMPARATOR
Intervention: Educational-based interventions
Number of subjects: 12
Study 15151349 — intervention group
Group type: COMPARATOR
Intervention: Office-based interventions
Number of subjects: 12
Study 11890650 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (TNF inhibitor)
Number of subjects: 0
Study 11890650 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (TNF inhibitor)
Number of subjects: 0
Study 9596436 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical CPR (TCPR)
Number of subjects: 20
Study 9596436 — intervention group
Group type: COMPARATOR
Intervention: Human/manual CPR (HCPR)
Number of subjects: 20
Study 7930736 — intervention group
Group type: EXPERIMENTAL
Intervention: Folinic acid with trimethoprim-sulfamethoxazole
Number of subjects: 92
Study 7930736 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo with trimethoprim-sulfamethoxazole
Number of subjects: 92
Study 3283292 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (450 mg daily in three divided doses)
Number of subjects: 8
Study 3283292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31644512 — intervention group
Group type: EXPERIMENTAL
Intervention: Spritztube tracheal cannula
Number of subjects: 334
Study 31644512 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal Mask Airway Supreme (LMA-S)
Number of subjects: 334
Study 27920262 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise programme filmed on an electronic tablet with automated reminders (n=30)
Number of subjects: 62
Study 27920262 — intervention group
Group type: COMPARATOR
Intervention: Standard paper-based home exercise programme (n=32)
Number of subjects: 62
Study 26159792 — intervention group
Group type: EXPERIMENTAL
Intervention: Uric Acid (UA) 1000 mg
Number of subjects: 206
Study 26159792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 24326529 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynocular
Number of subjects: 540
Study 24326529 — intervention group
Group type: COMPARATOR
Intervention: Stationary colposcope
Number of subjects: 540
Study 24326529 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy
Number of subjects: 540
Study 24326529 — intervention group
Group type: COMPARATOR
Intervention: Liquid-based cytology
Number of subjects: 540
Study 24326529 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing
Number of subjects: 540
Study 22045779 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrevocable ostracism by an outgroup (based on nationality)
Number of subjects: 0
Study 22045779 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrevocable ostracism by an outgroup (based on personal preferences)
Number of subjects: 0
Study 22045779 — intervention group
Group type: EXPERIMENTAL
Intervention: Ostracism by the ingroup
Number of subjects: 0
Study 22045779 — intervention group
Group type: EXPERIMENTAL
Intervention: Ostracism based on being 'too good' for the group
Number of subjects: 0
Study 19074207 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea catechin beverage (625 mg of catechins with 39 mg caffeine)
Number of subjects: 132
Study 19074207 — intervention group
Group type: COMPARATOR
Intervention: Control beverage (39 mg caffeine, no catechins)
Number of subjects: 132
Study 19074207 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea catechin beverage
Number of subjects: 132
Study 19074207 — intervention group
Group type: COMPARATOR
Intervention: Control beverage
Number of subjects: 132
Study 18024494 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial septal pacing
Number of subjects: 43
Study 18024494 — intervention group
Group type: COMPARATOR
Intervention: High right atrial pacing
Number of subjects: 43
Study 14971832 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 2750
Study 11564123 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam 1,000 mg/day
Number of subjects: 904
Study 11564123 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam 2,000 mg/day
Number of subjects: 904
Study 11564123 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam 3,000 mg/day
Number of subjects: 904
Study 11564123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 904
Study 9040320 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 micrograms of the new hepatitis B vaccine
Number of subjects: 100
Study 9040320 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms of the new hepatitis B vaccine
Number of subjects: 100
Study 9040320 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms of the new hepatitis B vaccine
Number of subjects: 100
Study 9040320 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 micrograms of the new hepatitis B vaccine
Number of subjects: 100
Study 9040320 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms of the new hepatitis B vaccine (single dose)
Number of subjects: 100
Study 8176527 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm water compress
Number of subjects: 73
Study 8176527 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm moist tea bag compress
Number of subjects: 73
Study 8176527 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressed milk massaged into the nipple and areola and air dried
Number of subjects: 73
Study 8176527 — intervention group
Group type: COMPARATOR
Intervention: Instruction only (control group)
Number of subjects: 73
Study 2976406 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin (30 mg/day initial dose for 4 weeks, mean dose 30.7 mg/day at end of study)
Number of subjects: 20
Study 2976406 — intervention group
Group type: COMPARATOR
Intervention: Etretinate (initial dose not specified, mean dose 33.4 mg/day at end of study)
Number of subjects: 20
Study 28815689 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation
Number of subjects: 98
Study 28815689 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 98
Study 27264224 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg subcutaneous injections
Number of subjects: 968
Study 27264224 — intervention group
Group type: COMPARATOR
Intervention: Placebo subcutaneous injections
Number of subjects: 968
Study 25016509 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine
Number of subjects: 40
Study 25016509 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 40
Study 22948196 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral intake of 2 L of 0.9% saline
Number of subjects: 10
Study 22948196 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion of 2 L of 0.9% saline
Number of subjects: 10
Study 21191426 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination niacin extended-release + simvastatin (NER/S)
Number of subjects: 137
Study 21191426 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 40 mg/day
Number of subjects: 137
Study 18762754 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.6 microg kg(‐1) as bolus before induction and 0.2 microg kg(‐1) h(‐1) by infusion
Number of subjects: 50
Study 18762754 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 1 microg kg(‐1) as bolus before induction and 0.5 microg kg(‐1) h(‐1) by infusion
Number of subjects: 50
Study 15915020 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg intravenous droperidol
Number of subjects: 120
Study 15915020 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg intravenous droperidol
Number of subjects: 120
Study 15915020 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 120
Study 15915020 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 120
Study 15915020 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol
Number of subjects: 120
Study 15915020 — intervention group
Group type: COMPARATOR
Intervention: Droperidol and saline
Number of subjects: 120
Study 12350439 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone operating
Number of subjects: 24
Study 12350439 — intervention group
Group type: COMPARATOR
Intervention: Mobile phone turned off
Number of subjects: 24
Study 9856967 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg moxonidine
Number of subjects: 25
Study 11785199 — intervention group
Group type: EXPERIMENTAL
Intervention: Alugastrin
Number of subjects: 110
Study 11785199 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrin
Number of subjects: 110
Study 11785199 — intervention group
Group type: EXPERIMENTAL
Intervention: Wikalina
Number of subjects: 110
Study 11785199 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 110
Study 11785199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 2744779 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (8 mg slow release twice daily)
Number of subjects: 15
Study 2744779 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (300 mg twice daily)
Number of subjects: 15
Study 984352 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentobarbitone (100 mg) given orally
Number of subjects: 0
Study 984352 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentobarbitone (100 mg) given intramuscularly
Number of subjects: 0
Study 984352 — intervention group
Group type: COMPARATOR
Intervention: Pentobarbitone (100 mg) organic preparation (Nembutal)
Number of subjects: 0
Study 984352 — intervention group
Group type: COMPARATOR
Intervention: Pentobarbitone (100 mg) aqueous solution
Number of subjects: 0
Study 984352 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentobarbitone (100 mg) injected by doctors
Number of subjects: 0
Study 984352 — intervention group
Group type: COMPARATOR
Intervention: Pentobarbitone (100 mg) injected by nurses
Number of subjects: 0
Study 984352 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 0
Study 29472259 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 66
Study 29472259 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 66
Study 26727407 — intervention group
Group type: EXPERIMENTAL
Intervention: Full Personalized Normative Feedback (PNF)
Number of subjects: 623
Study 26727407 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Personalized Social Comparison Feedback (PSCF)
Number of subjects: 623
Study 26727407 — intervention group
Group type: COMPARATOR
Intervention: Attention-control
Number of subjects: 623
Study 25092211 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wound infusion of ropivacaine (2 mL/hour of 0.375% ropivacaine after initial 10 mL of 0.75% ropivacaine)
Number of subjects: 0
Study 25092211 — intervention group
Group type: COMPARATOR
Intervention: Intermittent epidural ropivacaine (10 mL of 0.75% ropivacaine followed by 10 mL of 0.2% ropivacaine every 6 hours)
Number of subjects: 0
Study 22075651 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic interpersonal therapy (PIT), 12 weekly sessions
Number of subjects: 211
Study 22075651 — intervention group
Group type: COMPARATOR
Intervention: Enhanced medical care (EMC), 3 sessions
Number of subjects: 211
Study 22075651 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic interpersonal therapy (PIT)
Number of subjects: 211
Study 20977840 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-micronized BYHWD (5 g, twice a day) for 12 weeks
Number of subjects: 251
Study 20977840 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional BYHWD (15 g, twice a day) for 12 weeks
Number of subjects: 251
Study 20977840 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 251
Study 18985152 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual faces (avatars)
Number of subjects: 32
Study 18985152 — intervention group
Group type: COMPARATOR
Intervention: Natural human faces
Number of subjects: 32
Study 15804330 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate variability analysis using short ECG recordings
Number of subjects: 48
Study 15804330 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate variability analysis in diabetes group
Number of subjects: 48
Study 12576829 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic coated LoFric catheter
Number of subjects: 62
Study 12576829 — intervention group
Group type: COMPARATOR
Intervention: Standard plastic catheter
Number of subjects: 62
Study 11301846 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine in combination with cisplatin
Number of subjects: 0
Study 11301846 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin alone
Number of subjects: 0
Study 11301846 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus etoposide
Number of subjects: 0
Study 11301846 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus vinorelbine
Number of subjects: 0
Study 11301846 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus mitomycin and ifosfamide
Number of subjects: 0
Study 11301846 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine regimens
Number of subjects: 0
Study 9112100 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive videodisc programs designed to reduce HIV/STD risk behaviors
Number of subjects: 827
Study 8466735 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine SRO at 2.5 mg/day (increased to 5 mg/day if DBP remained above 90 mm Hg after 4 weeks)
Number of subjects: 52
Study 8466735 — intervention group
Group type: COMPARATOR
Intervention: Enalapril at 10 mg/day (increased to 20 mg/day if DBP remained above 90 mm Hg after 4 weeks)
Number of subjects: 52
Study 3553316 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 45
Study 3553316 — intervention group
Group type: EXPERIMENTAL
Intervention: Dothiepin
Number of subjects: 45
Study 3553316 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 45
Study 3553316 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study 31356456 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 30
Study 31356456 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 30
Study 30111378 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate prophylactic application of incisional Negative-pressure Wound Therapy (iNPWT) following ILND
Number of subjects: 0
Study 30111378 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative treatment
Number of subjects: 0
Study 27457478 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-Family Group (MFG) intervention
Number of subjects: 32
Study 27457478 — intervention group
Group type: COMPARATOR
Intervention: Active SCI education control (SCIEC)
Number of subjects: 32
Study 25444821 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-valent pneumococcal conjugate vaccine (PCV-9)
Number of subjects: 0
Study 25444821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22883166 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo with 20 mmHg cuff pressure
Number of subjects: 12
Study 22883166 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo with 40 mmHg cuff pressure
Number of subjects: 12
Study 22883166 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo with 60 mmHg cuff pressure
Number of subjects: 12
Study 22883166 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C with 60 mmHg cuff pressure
Number of subjects: 12
Study 22883166 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no cuff pressure)
Number of subjects: 12
Study 20828877 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 122
Study 20828877 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 122